Leveraging implementation and behavioral science to reduce harmful overuse of diagnostic testing in critically ill children

利用实施和行为科学来减少危重儿童过度使用诊断测试的有害情况

• 批准号: 10544171
• 负责人: Charlotte Z Woods-Hill
• 金额: $ 17.77万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-01 至 2025-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10544171
• 关键词: Address; Adverse drug event; Antibiotic Resistance; Antibiotics; Award; Bacteremia; Behavior; Behavioral; Behavioral Sciences; Belief; Blood; Caring; Cessation of life; Childhood; Clinical; Clinical Trials; Clinical effectiveness; Cluster randomized trial; Cognitive; Communicable Diseases; Complex; Consensus; Consolidated Framework for Implementation Research; Coupling; Critical Care; Critically ill children; Data; Decision Making; Diagnosis; Diagnostic; Diagnostic tests; Effectiveness; Enrollment; Foundations; Fright; Funding; Goals; Guidelines; Healthcare; Heart failure; Hospitalized Child; Hybrids; Incidence; Interview; Investigation; Knowledge; Laboratories; Length of Stay; Link; Maps; Medical; Mentors; Methods; Morbidity - disease rate; Outcome; Patient-Focused Outcomes; Patients; Pattern; Pediatric Hospitals; Pediatric Intensive Care Units; Pennsylvania; Performance; Philadelphia; Pilot Projects; Population; Prevalence; Proctor framework; Qualitative Methods; Quasi-experiment; Randomized; Research Methodology; Research Personnel; Resources; Respiratory Failure; Risk; Safety; Scientist; Self Efficacy; Sepsis; Series; Signs and Symptoms; Site; Symptoms; Testing; Uncertainty; United States; United States Agency for Healthcare Research and Quality; Universities; Variant; Work; cost; design; diagnosis standard; effectiveness research; experience; implementation design; implementation framework; implementation science; implementation strategy; implementation trial; improved; mortality; overtreatment; patient safety; pediatric sepsis; provider factors; skills; theories; trial design; unnecessary treatment

Project Abstract Overtreatment – health care in which the benefit does not outweigh risks – accounts for up to $200 billion annually in the United States, and is associated with worse outcomes and death. Unnecessary use of diagnostic testing is a primary driver of overtreatment. Diagnosing and treating suspected sepsis exemplifies this challenge. In hospitalized children, severe sepsis is common (8.2% prevalence) and deadly (25% mortality rate). Pediatric hospitals prioritize early sepsis recognition and rapid antibiotic administration as key performance metrics. Signs and symptoms of sepsis in children, however, are non-specific. The resulting diagnostic uncertainty may lead to harmful overtreatment. Blood cultures are the gold standard for diagnosing sepsis due to bacteremia. Frequently, clinicians obtain blood cultures and simultaneously start empiric broad-spectrum antibiotics. Only 5-15% of cultures will be positive, however, and up to 50% of those are actually falsely positive. False positive results lead to unnecessary antibiotics, increased lengths of stay, and increased costs. Reduction in unnecessary blood cultures in pediatric intensive care unit patients is feasible and safe, but current practice patterns for blood culture use vary widely, and culture use may be driven by reflexive behavior and fear of missing sepsis. With my Primary Mentor, I have been leading an AHRQ-funded 14-site PICU blood culture quality improvement collaborative called Bright STAR (R18 HS025642-01) since 2017. I will now leverage Bright STAR to 1) investigate what leads to blood culture overuse in the PICU, and 2) develop and test strategies to safely reduce blood culture overuse. I will use the Consolidated Framework for Implementation Research, the concept of cognitive bias, and the Proctor implementation framework to accomplish these objectives, in a series of qualitative, quantitative, and quasi-experimental research investigations. This proposal will give me experience in: applying frameworks of implementation/behavioral science, conducting mixed methods studies, designing implementation strategies, and conducting a clinical trial. These skills are critical to achieving my long term goal: to design and test strategies to safely reduce harmful overuse of other unnecessary diagnostic tests (and consequently, unnecessary treatments) in critically ill children. I will be mentored by a team of highly funded, successful researchers with expertise in infectious diseases, implementation science, behavioral science, trial design, and mixed methods research. I will have the full support of the Division of Critical Care at The Children's Hospital of Philadelphia and the University of Pennsylvania, with access to innumerable resources (such as the Penn Implementation Science Center, the Center for Pediatric Clinical Effectiveness research, and the Penn Mixed-Methods Laboratory) to help me accomplish my aims. I will use this award to become an independent implementation scientist improving patient outcomes by reducing harmful overuse of unnecessary tests in critically ill children on a large scale.

项目摘要 过度治疗--好处不大于风险的医疗保健--占到了2000亿美元 在美国每年发生一次，并且与更糟糕的结果和死亡相关。不必要的诊断 检测是过度治疗的主要驱动力。 诊断和治疗疑似脓毒症加剧了这一挑战。在住院的儿童中， 常见（8.2%患病率）和致命（25%死亡率）。儿科医院优先考虑早期脓毒症识别 和快速抗生素给药作为关键性能指标。儿童败血症的体征和症状， 然而，它们是非特异性。由此产生的诊断不确定性可能导致有害的过度治疗。 血培养是诊断菌血症引起脓毒症的金标准。通常，临床医生会采集血液 培养，同时开始经验性广谱抗生素。只有5-15%的培养物是阳性的， 然而，其中高达50%实际上是假阳性。假阳性结果导致不必要的 抗生素，住院时间延长，费用增加。减少儿科不必要的血培养 重症监护病房患者是可行和安全的，但目前的实践模式，血培养的使用差异很大， 而培养物的使用可能是由反射性行为和害怕遗漏脓毒症所驱动的。 在我的初级导师的帮助下，我一直在领导AHRQ资助的14个地点的PICU血液培养质量改进 自2017年以来，该合作称为Bright星星（R18 HS 025642 -01）。我现在将利用Bright星星来1） 调查导致PICU过度使用血培养的原因，2）制定和测试策略， 血培养过度使用。我将使用实施研究的综合框架， 认知偏差，以及普罗克特实现这些目标的框架，在一系列的 定性，定量和准实验研究调查。 这个建议将给我的经验：应用实施/行为科学的框架，进行 混合方法研究，设计实施策略，并进行临床试验。这些技能是 这对实现我的长期目标至关重要：设计和测试策略，以安全地减少有害的过度使用 其他不必要的诊断测试（因此，不必要的治疗）在重症儿童。我 将由一个拥有传染病专业知识的高资金，成功的研究人员团队指导， 实施科学、行为科学、试验设计和混合方法研究。我会得到你们的全力支持 费城儿童医院和宾夕法尼亚大学重症监护科的负责人， 访问无数的资源（如宾夕法尼亚实施科学中心，儿科中心 临床有效性研究，和宾夕法尼亚大学混合方法实验室），以帮助我实现我的目标。我会 利用这个奖项，成为一个独立的实施科学家，通过减少 对重症儿童大规模使用不必要的检查是有害的。